Novel Estrogen Receptor-Targeted Agents for Breast Cancer

Patel HK, Bihani T. Selective estrogen receptor modulators (SERMs) and selective estrogen receptor degraders (SERDs) in cancer treatment. Pharmacol Ther. 2018;186:1–24.

Article  CAS  PubMed  Google Scholar 

Heldring N, Pike A, Andersson S, et al. Estrogen receptors: how do they signal and what are their targets. Physiol Rev. 2007;87:905–31.

Article  CAS  PubMed  Google Scholar 

Hall JM, McDonnell DP. Coregulators in nuclear estrogen receptor action: from concept to therapeutic targeting. Mol Interv. 2005;5:343–57.

Article  PubMed  Google Scholar 

Carroll JS, Meyer CA, Song J, Li W, Geistlinger TR, Eeckhoute J. Genome- wide analysis of estrogen receptor binding sites. Nat Genet. 2006;38:1289–97.

Article  CAS  PubMed  Google Scholar 

Ikeda K, Horie-Inuoe K, Inuoe S. Identification of estrogen-responsive genes based on DNA binding properties of estrogen receptors using high-throughput sequencing technology. Acta Pharmacol Sin. 2015;36:24–31.

Article  CAS  PubMed  Google Scholar 

Gottardis MM, Robinson SP, Satyaswaroop PG, Jordan VC. Contrasting actions of tamoxifen on endometrial and breast tumor growth in the athymic mouse. Cancer Res. 1988;48:812–5.

CAS  PubMed  Google Scholar 

Love RR, Mazess RB, Barden HS, et al. Effects of tamoxifen on bone mineral density in postmenopausal women with breast cancer. N Engl J Med. 1992;326:852–6.

Article  CAS  PubMed  Google Scholar 

McDonnell DP, Wardell SE, Norris JD. Oral selective estrogen receptor downregulators (SERDs), a breakthrough endocrine therapy for breast cancer. J Med Chem. 2015;58:4883–7.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Musgrove EA, Sutherland RL. Biological determinants of endocrine resistance in breast cancer. Nat Rev Cancer. 2009;9:631–43.

Article  CAS  PubMed  Google Scholar 

Jeselsohn R, Yelensky R, Buchwalter G, et al. Emergence of constitutively active estrogen receptor-α mutations in pretreated advanced estrogen receptor positive breast cancer. Clin Cancer Res. 2014;20:1757–67.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Toy W, Shen Y, Won H, et al. ESR1 ligand binding domain mutations in hormone resistant breast cancer. Nat Genet. 2013;45:1439–45.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Fawell SE, White R, Hoare S, et al. Inhibition of estrogen receptor-DNA binding by the "pure" antiestrogen ICI 164,384 appears to be mediated by impaired receptor dimerization. Proc Natl Acad Sci U S A. 1990;87:6883–7.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Dauvois S, White R, Parker MG. The antiestrogen ICI 182780 disrupts estrogen receptor nucleocytoplasmic shuttling. J Cell Sci. 1993;106:1377–88.

Article  CAS  PubMed  Google Scholar 

Osborne C, Wakeling A, Nicholson R. Fulvestrant: an oestrogen receptor antagonist with a novel mechanism of action. Br J Cancer. 2004;90:S2–6.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Long X, Nephew KP. Fulvestrant (ICI 182,780)-dependent interacting proteins mediate immobilization and degradation of estrogen receptor. J Biol Chem. 2006;281:9607–15.

Article  CAS  PubMed  Google Scholar 

Di Leo A, Jerusalem G, Petruzelka L, et al. Results of the CONFIRM Phase III Trial comparing fulvestrant 250 mg with fulvestrant 500 mg in postmenopausal women with estrogen receptor–positive advanced breast cancer. J Clin Oncol. 2010;28:4594–600.

Article  PubMed  Google Scholar 

Robertson JF, Lindemann J, Garnett S, et al. A good drug made better: the fulvestrant dose-response story. Clin Breast Cancer. 2014;14:381–9.

Article  CAS  PubMed  Google Scholar 

Fribbens C, O’Leary B, Kilburn L, et al. Plasma ESR1 mutations and the treatment of estrogen receptor–positive advanced breast cancer. J Clin Oncol. 2016;34:2961–8.

Article  CAS  PubMed  Google Scholar 

Harrison M, Laight A, Clarke D, et al. Pharmacokinetics and metabolism of fulvestrant after oral, intravenous and intramuscular administration in healthy volunteers. Eur J Cancer Suppl. 2003;1:S171.

Article  Google Scholar 

Mottamal M, Kang B, Peng X, Wang G. From pure antagonists to pure degraders of the estrogen receptor: evolving strategies for the same target. ACS Omega. 2021;6:9334–43. A mini-review discussing the chemical structure anti-estrogen therapies and the development of oral SERDs.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Bentrem DJ, Dardes RC, Liu H, et al. Molecular mechanism of action at estrogen receptor α of a new clinically relevant antiestrogen (GW7604) related to tamoxifen1. Endocrinology. 2001;142:838–46.

Article  CAS  PubMed  Google Scholar 

Wu YL, Yang X, Ren Z, McDonnell DP, et al. Structural basis for an unexpected mode of SERM-mediated ER antagonism. Molecular Cell. 2005;18:413–24.

Article  CAS  PubMed  Google Scholar 

Connor CE, Norris JD, Broadwater G, et al. Circumventing tamoxifen resistance in breast cancers using antiestrogens that induce unique conformational changes in the estrogen receptor. Cancer Res. 2001;61:2917–22.

CAS  PubMed  Google Scholar 

Dardes RC, O'Regan RM, Gajdos C, et al. Effects of a new clinically relevant antiestrogen (GW5638) related to tamoxifen on breast and endometrial cancer growth in vivo. Clin Cancer Res. 2002;8:1995–2001.

CAS  PubMed  Google Scholar 

Wardell SE, Ellis MJ, Alley HM, et al. Efficacy of SERD/SERMhybrid-CDK4/6 inhibitor combinations in models of endocrine therapy-resistant breast cancer. Clin Cancer Res. 2015a;21:5121–30.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Garner F, Shomali M, Paquin D, et al. RAD1901: A novel, orally bioavailable selective estrogen receptor degrader that demonstrates antitumor activity in breast cancer xenograft models. Anticancer Drugs. 2015;26:948–56.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Bihani T, Patel HK, Arlt H, et al. Elacestrant (RAD1901), a selective estrogen receptor degrader (SERD), has antitumor activity in multiple ER1 breast cancer patient-derived xenograft models. Clin Cancer Res. 2017;23:4793–804.

Article  CAS  PubMed  Google Scholar 

Wardell SE, Nelson ER, Chao CA, et al. Evaluation of the pharmacological activities of RAD1901, a selective estrogen receptor degrader. Endocr-Relat Cancer. 2015b;22:713–24.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Bardia A, Kaklamani V, Wilks S, et al. Phase I study of elacestrant (RAD1901), a novel selective estrogen receptor degrader, in ER-Positive, HER2-Negative advanced breast cancer. J Clin Oncol. 2021;39:1360–70.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Bidard F-C, Kaklamani VG, Neven P, et al. Elacestrant (oral selective estrogen receptor degrader) versus standard endocrine therapy for estrogen receptor–positive, human epidermal growth factor receptor 2–negative advanced breast cancer: results from the randomized phase III EMERALD trial. J Clin Oncol. 2022;40(28):3246–56. Results from the first phase III trial of an oral SERD compared to standard of care endocrine therapy in ER+/HER2- MBC.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Sanchez KG, Nangia JR, Schiff R, Rimawi MF. Elacestrant and the promise of oral SERDs. J Clin Oncol. 2022;40(28):3227–9.

Article  PubMed  Google Scholar 

Kaklamani VG, Bardia A, Aftimos PG et al. Subgroup analysis of patients with no prior chemotherapy in EMERALD: a phase 3 trial evaluating elacestrant, an oral selective estrogen receptor degrader (SERD), versus investigator’s choice of endocrine monotherapy for ER+/HER2-advanced/metastatic breast cancer (mBC). J Clin Oncol 2021;40(no. 16_suppl):1100.

Metcalfe C, Ingalla E, Blake R, et al. GDC-9545: A novel ER antagonist and clinical candidate that combines desirable mechanistic and pre-clinical DMPK attributes. Cancer Res. 2019;79:P5-04-07. Abstract P5-04-07.

Article  Google Scholar 

Liang J, Zbieg JR, Blake RA, et al. GDC-9545 (Giredestrant): A potent and orally bioavailable selective estrogen receptor antagonist and degrader with an exceptional preclinical profile for ER+ breast cancer. J Med Chem. 2021;64(16):11841–56.

Article  CAS  PubMed  Google Scholar 

Jhaveri K, Boni V, Sohn J. Safety and activity of single-agent giredestrant (GDC-9545) from a phase Ia/b study in patients (pts) with estrogen receptorpositive (ER+), HER2-negative locally advanced/metastatic breast cancer (LA/mBC). J Clin Oncol. 2021;39:(no. 15_suppl):1017–7.

Article  Google Scholar 

Lim E, Jhaveri KL, Perez-Fidalgo JA, et al. A phase Ib study to evaluate the oral selective estrogen receptor degrader GDC- 9545 alone or combined with palbociclib in metastatic ER-positive HER2- negative breast cancer. J Clin Oncol. 2020;38(15_suppl):1023.

Article  Google Scholar 

Martin JM, Lim E, Chavez MM, et al. Giredestrant (GDC-9545) vs physician choice of endocrine monotherapy (PCET) in patients (pts) with ER+, HER2–locally advanced/metastatic breast cancer (LA/mBC): primary analysis of the phase II, randomised, open-label acelERA BC study. Ann Oncol. 2022;33(suppl_7):S88–S121.

Google Scholar 

Shomali M, Cheng J, Sun F, et al. SAR439859, a novel selective estrogen receptor degrader (SERD), demonstrates effective and broad antitumor activity in wild-type and mutant ER-positive breast cancer models. Mol Cancer Ther. 2021;20(2):250–62.

留言 (0)

沒有登入
gif